The Advisory Committee on Immunization Practices (ACIP) recommends vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion have risk factors for HBV infection and vaccination of adults requesting protection from HBV without acknowledgment of a specific risk factor. Michelle Sherman, RPh., is a pharmacist expert in HIV & HEP-C treatment protocols & is the host of the Conscious Pharmacist Podcast. Michelle is the special...
The Advisory Committee on Immunization Practices (ACIP) recommends vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion have risk factors for HBV infection and vaccination of adults requesting protection from HBV without acknowledgment of a specific risk factor. Michelle Sherman, RPh., is a pharmacist expert in HIV & HEP-C treatment protocols & is the host of the Conscious Pharmacist Podcast. Michelle is the special co-host of today's discussion on the proposed impact of universal Hepatitis B Vaccinations.
About our guest: Catherine Stevenson is Director of Corporate Strategy at Dynavax Technologies, a California-based biotechnology company which has developed and commercialized a 2-dose Hepatitis-B vaccine. With a Masters in Health and Science Policy, her background spans over 10 years of working in biotechnology, non-profits, and scientific research.
Referenced Journal Articles:
Stevenson C, Youn JH, Hayney MS, David C. Preventing hepatitis B virus infection among healthcare professionals: potential impact of a 2-dose versus 3-dose vaccine. Hum Vaccin Immunother. 2021
Stevenson C, de la Rosa G, Anderson CS, Murphy PS, Capece T, Kim M, Elliott MR. Essential role of Elmo1 in Dock2-dependent lymphocyte migration. J Immunol. 2014 Jun 15;192(12):6062-70.
Bradel-Tretheway BG, Mattiacio JL, Krasnoselsky A, Stevenson C, Purdy D, Dewhurst S, Katze MG. Comprehensive proteomic analysis of influenza virus polymerase complex reveals a novel association with mitochondrial proteins and RNA polymerase accessory factors. J Virol. 2011 Sep;85(17):8569-81.
Zhou T, Zheng A, Baxa U, Chuang GY, Georgiev IS, Kong R, O'Dell S, Shahzad-Ul-Hussan S, Shen CH, Tsybovsky Y, Bailer RT, Gift SK, Louder MK, McKee K, Rawi R, Stevenson CH, Stewart-Jones GBE, Taft JD, Waltari E, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CD, Wu CY; NISC Comparative Sequencing Program, Mullikin JC, Bewley CA, Burton DR, Polonis VR, Shapiro L, Wong CH, Mascola JR, Kwong PD, Wu X. A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. Immunity. 2018 Mar 20;48(3):500-513.e6.
Contributing Posts:
Stevenson, C, P Peeples. “Real-world evidence and value-based contracting – swipe left or swipe right?” https://www.healtheconomics.com/blog/2019/02/real-world-evidence-and-value-based-contracting-swipe-left-or-swipe-right/.
Stevenson, C, P Peeples. “Pharmacy Benefit Managers: A Mechanism for Containing Costs or a Contributor to Rising Drug Prices?” L https://www.healtheconomics.com/industry-news/pharmacy-benefit-managers-a-mechanism-for-containing-costs-or-a-contributor-to-rising-drug-prices.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View more